

Date Collected: 01/02/2024

Date Received: 01/02/2024

Date Reported: 01/07/2024

Fasting: Yes

Ordered Items: OmegaCheck(TM) (EPA+DPA+DHA); Lipoprotein (a); C-Reactive Protein, Cardiac; Homocyst(e)ine; Venipuncture

Date Collected: 01/02/2024

OmegaCheck(TM) (EPA+DPA+DHA)

Test	Current Result and Flag		Previous Result and Date	Units	Reference Interval
▼ OmegaCheck(TM) ⁰¹	4.8	Low		% by wt	>5.4
Relative Risk: MOD Increasing blood levels of long-chain n-3 fatty acids are associated with a lower risk of sudden cardiac death (1). Based on the top (75th percentile) and bottom (25th percentile) quartiles of the CHL reference population, the following risk categories were established for OmegaCheck: A cut-off of >=5.5% by wt defines a population at low relative risk, 3.8-5.4% by wt defines a population at moderate relative risk, and <=3.7% by wt defines a population at high relative risk of sudden cardiac death. The totality of the scientific evidence demonstrates that when consumption of fish oils is limited to 3 g/day or less of EPA and DHA, there is no significant risk for increased bleeding time beyond the normal range. A daily dosage of 1 gram of EPA and DHA lowers the circulating triglycerides by about 7-10% within 2 to 3 weeks. (Reference: 1-Albert et al. NEJM. 2002; 346: 1113-1118).					
Arachidonic Acid/EPA Ratio ⁰¹	13.5				3.7-40.7
Omega-6/Omega-3 Ratio ⁰¹	7.6				3.7-14.4
Omega-3 total ⁰¹	4.8			% by wt	
EPA ⁰¹	0.8			% by wt	0.2-2.3
DPA ⁰¹	1.4			% by wt	0.8-1.8
DHA ⁰¹	2.6			% by wt	1.4-5.1
Omega-6 total ⁰¹	37.0			% by wt	
Cleveland HeartLab measures a number of omega-6 fatty acids with AA and LA being the two most abundant forms reported.					
Arachidonic Acid ⁰¹	11.3			% by wt	8.6-15.6
Linoleic Acid ⁰¹	22.8			% by wt	18.6-29.5
This test is performed by a Liquid Chromatography-Tandem Mass Spectrometry (LC/MS/MS) method. This test was developed and its performance characteristics determined by the Cleveland HeartLab, Inc. It has not been cleared or approved by the U.S. FDA. The Cleveland HeartLab is regulated under Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.					
PDF ⁰¹	.				

Lipoprotein (a)

Test	Current Result and Flag		Previous Result and Date	Units	Reference Interval
▲ Lipoprotein (a) ⁰²	196.0	High		nmol/L	<75.0
Note: Values greater than or equal to 75.0 nmol/L may					

Date Collected: 01/02/2024

Lipoprotein (a) (Cont.)

indicate an independent risk factor for CHD, but must be evaluated with caution when applied to non-Caucasian populations due to the influence of genetic factors on Lp(a) across ethnicities.

C-Reactive Protein, Cardiac

Test	Current Result and Flag		Previous Result and Date		Units	Reference Interval
▲ C-Reactive Protein, Cardiac ⁰³	6.17	High	0.85	12/08/2022	mg/L	0.00-3.00
Relative Risk for Future Cardiovascular Event						
Low					<1.00	
Average					1.00 - 3.00	
High					>3.00	

Homocyst(e)ine

Test	Current Result and Flag		Previous Result and Date		Units	Reference Interval
Homocyst(e)ine ⁰³	7.5		9.3	12/08/2022	umol/L	0.0-14.5

Disclaimer
The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

Icon Legend
▲ Out of Reference Range ■ Critical or Alert

Performing Labs
01: CLHRT - Cleveland Heartlab Inc, 6701 Carnegie Avenue Ste 500, Cleveland, OH 44103-4623 Dir: Bill Richendollar, MD
02: BN - Labcorp Burlington, 1447 York Court, Burlington, NC 27215-3361 Dir: Sanjai Nagendra, MD
03: MB - Labcorp Birmingham, 1801 First Avenue South, Birmingham, AL 35233-1935 Dir: Steven Wang, MD
For Inquiries, the physician may contact Branch: 615-366-0313 Lab: 205-581-3500

<div>Patient Details</div> <div>Brakefield, Stephanie H</div> <div>901 CANTRELL AVE, NASHVILLE, TN, 37215</div> <div>Phone: 615-485-3415</div> <div>Date of Birth: 07/17/1963</div> <div>Age: 60</div> <div>Sex: Female</div> <div>Patient ID: 10199C41383675</div> <div>Alternate Patient ID: 10199C41383675</div>	<div>Physician Details</div> <div>L LAVIN</div> <div>David Haase Maxwell Clc PLLC</div> <div>103 Continental Pl Ste 300, Brentwood, TN, 37027</div> <div>Phone: 615-370-0091</div> <div>Account Number: 41383675</div> <div>Physician ID: 1124355730</div> <div>NPI: 1124355730</div>	<div>Specimen Details</div> <div>Specimen ID: 002-059-4491-0</div> <div>Control ID: 0000773012</div> <div>Alternate Control Number: 0000773012</div> <div>Date Collected: 01/02/2024 0923 Local</div> <div>Date Received: 01/02/2024 0000 ET</div> <div>Date Entered: 01/02/2024 1613 ET</div> <div>Date Reported: 01/07/2024 0635 ET</div>
---	---	---

Historical Results & Insights

Labcorp offers historical lab results data with easy-to-interpret visualizations to provide a more complete picture of a patient’s lab history and improve patient care.

Cardiovascular Tests

Date	hs-CRP
01/02/2024†	6.17
12/08/2022†	0.85
09/17/2021†	1.00
02/03/2021†	0.53
02/13/2019†	0.57
Ref. Interval	0.00-3.00
Units	mg/L
† Fasting	

Patient Information	Specimen Information	Client Information
BRAKEFIELD, STEPHANIE H DOB: 07/17/1963 AGE: 60 Gender: Female Fasting: Fasting Phone: Patient ID: 2400205944910	Order ID: 2400302253 Requisition: 2400302253 Collected: 01/02/2024, 09:23 AM Received: 01/05/2024, 2:28 PM Reported: 01/07/2024, 00:42 AM	PROVIDER LABCORP 11737 LABCORP BIRMINGHAM 1801 FIRST AVENUE SOUTH BIRMINGHAM, AL 35233

Cardiometabolic Report

Test Name	Current		Reference Range/Relative Risk Categories				Historical	
	Result & Relative Risk		Optimal	Moderate	High	Units	Result & Relative Risk	
	Optimal	Non-Optimal					//	//
FATTY ACIDS								
OmegaCheck® (Whole Blood: EPA+DPA+DHA) ⁽¹⁾		4.8	≥5.5	3.8-5.4	≤3.7	% by wt		
Arachidonic Acid/EPA Ratio	13.5			3.7-40.7				
Omega-6/Omega-3 Ratio	7.6			3.7-14.4				
Omega-3 total		4.8				% by wt		
EPA	0.8			0.2-2.3		% by wt		
DPA	1.4			0.8-1.8		% by wt		
DHA	2.6			1.4-5.1		% by wt		
Omega-6 total		37.0				% by wt		
Arachidonic Acid	11.3			8.6-15.6		% by wt		
Linoleic Acid	22.8			18.6-29.5		% by wt		

UND = UNDETECTABLE

INC = INCOMPUTABLE

Medical Information For Healthcare Providers: If you have any questions about any of the tests in our Cardiometabolic Report, please call Cleveland HeartLab Client Services at 866.358.9828, option 1 to arrange a consult with our clinical education team.

Cardiometabolic Comment Report

FATTY ACIDS									
OmegaCheck® (Whole Blood: EPA+DPA+DHA) ⁽¹⁾									
Increasing blood levels of long-chain n-3 fatty acids are associated with a lower risk of sudden cardiac death (1). Based on the top (75th percentile) and bottom (25th percentile) quartiles of the CHL reference population, the following relative risk categories were established for OmegaCheck: A cut-off of >=5.5% by wt defines a population at optimal relative risk, 3.8-5.4% by wt defines a population at moderate relative risk, and <=3.7% by wt defines a population at high relative risk of sudden cardiac death. The totality of the scientific evidence demonstrates that when consumption of fish oils is limited to 3 g/day or less of EPA and DHA, there is no significant risk for increased bleeding time beyond the normal range. A daily dosage of 1 gram of EPA and DHA lowers the circulating triglycerides by about 7-10% within 2 to 3 weeks. (Reference: 1-Albert et al. NEJM. 2002; 346: 1113-1118).									
Omega-6 total									
Cleveland HeartLab measures a number of omega-6 fatty acids with AA and LA being the two most abundant forms reported.									

Patient Information	Specimen Information	Client Information
BRAKEFIELD, STEPHANIE H DOB: 07/17/1963 AGE: 60 Gender: Female Fasting: Fasting Patient ID: 2400205944910	Order ID: 2400302253 Collected: 01/02/2024, 09:23 AM Received: 01/05/2024, 2:28 PM Reported: 01/07/2024, 00:42 AM	PROVIDER LABCORP

Footnotes

(1) This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Cardiometabolic Center of Excellence at Cleveland HeartLab. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

PERFORMING SITE:

Z4M CLEVELAND HEARTLAB INC, 6701 CARNEGIE AVENUE SUITE 500, CLEVELAND, OH 44103-4623 Medical Director: Sami Albeiroti, PhD, D(ABCC) CLIA:36D1032987